LIBERIA: First 600 Ebola Trial Vaccines For Redemption Hospital

The first 600 Ebola vaccines in the clinical trial will be administered to volunteers at the newly-renovated clinical research unit of the Redemption Hospital in New Kru Town, authorities have said.
The Ebola vaccine trial is the result of a request from the Liberian Health Ministry to the U.S. Department of Health and Human Services to form a joint clinical research partnership to accelerate the development of a vaccine to prevent Ebola, Clifford Lane, U.S. Principal Investigator for the study, stated.
Speaking at the Ministry of Information daily Ebola press conference in Monrovia on Monday, Lane, who is also a Clinical Director at the US-based National Institute of Allergy and Infectious Disease, disclosed that the study is designed to determine, if the individual is given single dose of a test vaccine, it will prevent the Ebola virus.
He also revealed that the two vaccines, the ChAd3-ZEBOV, manufactured by GlaxoSmithKline, a British pharmaceutical company, and the rVSV-ZEBOV, manufactured by Merck/NewLink in Canada, were recognized by the WHO panel at the most advanced stage of development.
Lane indicated that the clinical development process for the vaccine began with a Phase One testing for safety in a small amount of human volunteers, adding that “several Phase One studies have been conducted with adverse effects, proving mild but did not last long.”

(Visited 27 times, 1 visits today)

Be the first to comment

Leave a Reply

Your email address will not be published.